Entering text into the input field will update the search result below

NLS Pharmaceutics Seeks $40 Million U.S. IPO


  • NLS Pharmaceutics has filed to raise development funding on U.S. capital markets.
  • The firm is advancing a pipeline of drug candidates for the treatment of narcolepsy and ADHD.
  • NLSP plans to begin pivotal trials for its narcolepsy treatment in late 2020.
  • Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »

Quick Take

NLS Pharmaceutics (NASDAQ:NLSP) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement.

The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders.

NLSP expects to begin pivotal trials for its lead candidate in late 2020.

When we learn more about the IPO’s details, I’ll provide a final opinion.

Company & Technology

Stans, Switzerland-based NLS was founded to develop treatments for central nervous system disorders.The firm's current area of focus is developing single molecules for the treatment of rare hypersomnia (excessive or uncontrollable daytime sleepiness, narcolepsy) and attention deficit hyperactivity disorder, or ADHD.

Management is headed by Chief Executive Officer Mr. Alexander Zwyer, who has been with the firm since 2015 and was previously at Viforpharma AG.

Below is a brief overview video of narcolepsy:

Source: Osmosis

The firm's primary candidates, Quilience for narcolepsy and Nolazol for ADHD, use a molecule Mazindol in a controlled release formulation.Mazindol has been used for the treatment of obesity and off-label for narcolepsy.NLSP intends to begin pivotal trials for Quilience in Q4 2020 and in Q4 2021 for Nolazol.

Investors in the firm have invested at least $20.5 million and include Magnetic Rock Investment and various individuals.

Market & Competition

According to a 2019 market research report by Allied Market Research, the market for narcolepsy treatment was $2.4 billion in 2018 and is forecast to reach $5.4 billion by 2026.

This represents a forecast CAGR (Compound Annual Growth Rate) of 10.3% from 2019 to 2026.

Key elements driving this expected growth are The narcolepsy drug market is segmented into the following parts:

  • Central nervous system stimulants (NLS’s candidates are in this category)

  • Tricyclic antidepressants

  • Sodium oxybate

  • Selective serotonin reuptake inhibitors [SSRIs]

  • Others

North America

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis. Get started with a free trial!

This article was written by

Donovan Jones profile picture

Donovan Jones is an IPO research specialist with 15 years of experience identifying opportunities for IPOs. He focuses on high-growth technology, consumer, and life science companies.

He leads the investing group IPO Edge which offers: actionable information on growth stocks through first look S-1 filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

The company announced an outlicensing deal with Eurofarma for Latin-America in 2019.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.